Obesity Linked to Subsequent Neoplasms in Childhood Cancer Survivors
By Elana Gotkine HealthDay Reporter
FRIDAY, June 6, 2025 -- Body mass index (BMI) and physical activity are associated with the risk for subsequent neoplasms among childhood cancer survivors, according to a study published online June 5 in JAMA Oncology.
Lenat Joffe, M.D., from Northwell in New Hyde Park, New York, and colleagues examined associations between time-varying BMI/physical activity and subsequent neoplasm risk among childhood cancer survivors in a retrospective cohort analysis. Five-year childhood cancer survivors diagnosed at younger than 21 years of age between 1970 and 1999 were enrolled and followed through September 2019.
Overall, 22,716 participants had BMI data before subsequent neoplasm development and met eligibility criteria for the study. The researchers found 2,554 subsequent neoplasms among 2,156 individuals (median age at subsequent neoplasm diagnosis, 37.4 years). Higher 30-year subsequent neoplasm cumulative incidence was seen for survivors reporting lower physical activity (18.6 percent for 0 metabolic equivalent hours/week [MET-h/wk] versus 10.9 percent for 15 to 21 MET-h/wk). Obese BMI was associated with increased incidence rates of solid organ, central nervous system (CNS), and skin subsequent neoplasms (relative rates, 1.22, 1.47, and 1.30, respectively). A protective association was seen for higher physical activity (15 to 21 MET-h/wk) for any, solid organ, CNS, and skin subsequent neoplasms (relative rates, 0.61, 0.65, 0.50, and 0.72, respectively). Specific associations were seen for BMI and physical activity with subsequent meningiomas and thyroid carcinomas, but not with breast or colorectal cancers or hematologic subsequent neoplasms.
"The findings of this cohort study indicated that BMI and physical activity may considerably impact subsequent neoplasm risk long after completion of therapy," the authors write.
Two authors disclosed ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-07 06:00
Read more

- FDA Grants Accelerated Approval to Avmapki Fakzynja Co-Pack (avutometinib capsules/defactinib tablets) for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
- Want To Live Longer? Stay Sociable, Study Says
- Biden’s Prostate Cancer Likely Grew Undetected for Years, Experts Say
- High-Volume Exercise Tied to Increased Coronary Artery Calcification Score
- Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
- Childhood Obesity Triples Odds Of Weight Discrimination
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions